Last update 01 Nov 2024

β2-adrenergic receptor x DRDs

Last update 01 Nov 2024

Basic Info

Related Targets

β2-adrenergic receptorDRDs

Drugs associated with β2-adrenergic receptor x DRDs

Phenylpropanolamine Hydrochloride

Target

ADRA1 x D1 receptor x α2A-AR x β1-adrenergic receptor x β2-adrenergic receptor

Mechanism

ADRA1 agonists [+4]

Active Org.-

Originator Org.-

Active Indication

Nasal Obstruction

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Dopexamine Hydrochloride

Target

DRDs x β2-adrenergic receptor

Mechanism

DRDs agonists [+1]

Active Org.-

Originator Org.-

Active Indication

Heart Failure

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Hydrocodone Bitartrate/Phenylpropanolamine Hydrochloride

Target

ADRA1 x D1 receptor x GR x α2A-AR x β1-adrenergic receptor x β2-adrenergic receptor

Mechanism

ADRA1 agonists [+5]

Active Org.-

Originator Org.-

Active Indication

Cough [+1]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with β2-adrenergic receptor x DRDs

NCT01418118 / CompletedPhase 4IIT

An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study

Following surgery to remove tumours of the head and neck, patients undergo reconstruction with free flaps - tissue that is taken from elsewhere in the body and given a new blood supply by attaching it to vessels in the neck. Following this type of surgery, patients often need medication to maintain their blood pressure in the intensive care unit. The effect of these drugs on the transplanted tissues is unknown. This study investigates the effects of four commonly used drugs on free flap perfusion.

Start Date01 Oct 2008

Sponsor / Collaborator

Oxford University Hospitals NHS Trust

100 Clinical Results associated with β2-adrenergic receptor x DRDs

100 Translational Medicine associated with β2-adrenergic receptor x DRDs

0 Patents (Medical) associated with β2-adrenergic receptor x DRDs

Literatures (Medical) associated with β2-adrenergic receptor x DRDs

06 Jun 2024·Journal of Pharmacy and Pharmacology

Integrating metabolomics and network pharmacology to assess the effects of Mahuang Xixin Fuzi decoction on migraine rats induced by nitroglycerin

Article

Author: Zhang, Yao ; Ge, Fei ; Wang, Chunguo ; Chen, Meng ; Luo, Yamin ; Lu, Yixing ; Zhang, Di ; Meng, Fengxian ; Zhang, Dongmei ; Tao, Xiaohua ; Zhao, Yafang

AbstractObjectivesThis study was designed to investigate the pharmacological activity and therapeutic mechanism of Mahuang Xixin Fuzi decoction (MXFD) on migraine.MethodsMigraine model rats induced by nitroglycerin were established, and then orally administered with MXFD for 7 days. Blood and urine samples were collected to identify differential metabolites with metabolomics. To integrate the findings from network pharmacology and metabolomics analysis, the metabolites and targets related to MXFD therapy for migraine were filtered.Key findingsMXFD was found to alleviate the symptoms of migraines in rats. After treatment with MXFD, nine metabolites were found to be regulated and returned to normal levels. MXFD acted directly on nine key targets including MAOB, MAOA, ADRB1, ADRB2, ADRB3, ADORA2A, ADORA2B, DRD5, and HTR4 and regulated two out of nine metabolites, namely deoxycholic acid and 5-methoxyindoleacetate.ConclusionsThe study found that MXFD can alleviate migraines through multitarget and multicomponent interaction networks.

30 Apr 2024·Proceedings of the National Academy of Sciences

Single-chain fluorescent integrators for mapping G-protein-coupled receptor agonists

Article

Author: Shen, Jiaqi ; Fiel, Hailey ; Kroning, Kayla ; Wang, Wenjing ; Zhou, Guanwei ; Putansu, Aubrey ; Li, Xingyu ; Wilson, Avery ; Gannot, Noam ; Li, Peng ; Sescil, Jennifer

G protein-coupled receptors (GPCRs) transduce the effects of many neuromodulators including dopamine, serotonin, epinephrine, acetylcholine, and opioids. The localization of synthetic or endogenous GPCR agonists impacts their action on specific neuronal pathways. In this paper, we show a series of single-protein chain integrator sensors that are highly modular and could potentially be used to determine GPCR agonist localization across the brain. We previously engineered integrator sensors for the mu- and kappa-opioid receptor agonists called M- and K-Single-chain Protein-based Opioid Transmission Indicator Tool (SPOTIT), respectively. Here, we engineered red versions of the SPOTIT sensors for multiplexed imaging of GPCR agonists. We also modified SPOTIT to create an integrator sensor design platform called SPOTIT for all GPCRs (SPOTall). We used the SPOTall platform to engineer sensors for the beta 2-adrenergic receptor (B2AR), the dopamine receptor D1, and the cholinergic receptor muscarinic 2 agonists. Finally, we demonstrated the application of M-SPOTIT and B2AR-SPOTall in detecting exogenously administered morphine, isoproterenol, and epinephrine in the mouse brain via locally injected viruses. The SPOTIT and SPOTall sensor design platform has the potential for unbiased agonist detection of many synthetic and endogenous neuromodulators across the brain.

01 Jan 2024·Chemosphere

Exposure of embryos to fenbuconazole causes persistent neurotoxicity in adult zebrafish

Article

Author: Aihaiti, Ailifeire ; Zhang, Ying ; Li, Zihui ; Tang, Chen ; Wang, Chonggang

In this study, the persistent effects of embryonic exposure to fenbuconazole (FBZ), a triazole fungicide, on neurobehaviour in zebrafish were investigated. After exposure of fertilized eggs to FBZ for 72 h (h), the larvae were cultured to adulthood in clean water. In adult zebrafish embryonically exposed to 50 and 500 ng L^-1 FBZ, the ratio of brain weight/body weight was significantly decreased, and the number of apoptotic cells in the brain was significantly increased, accompanied by upregulated protein levels of P53 and downregulated levels of BCL2. The novel tank test showed a significant reduction in the moved distance and speed, and a longer period of adaptation to new environments in the 500 ng L^-1 group. The social preference experiment showed impaired social interaction behaviour and reduced time of aggregation in the 500 ng L^-1 group. Increased dopamine and norepinephrine levels in the brain might be responsible for this anxiety-like behaviour. In addition to upregulated protein levels of tyrosine hydroxylase and β₂-adrenoceptor, the transcription of genes related to dopamine and norepinephrine synthesis in the brain such as th1, th2, ddc, drd1b, dat, and dbh, was increased. The methylation levels of related genes were reduced, which were matched with their increased transcriptional levels. These results demonstrate that embryonic FBZ exposure might cause persistent neurotoxicity in adulthood, which suggests the rational cautious use of FBZ.

News (Medical) associated with β2-adrenergic receptor x DRDs

25 Jul 2023

·www.pharmaceutical-technology.com

Golgi and Breye partner to develop P2X7 receptor antagonist programme

Diabetic retinopathy is one of the main reasons for blindness among working-age adults. Credit: Alexander Grey from Pixabay. Golgi Neurosciences has joined forces with Breye Therapeutics for the development of a P2X7 receptor antagonist programme. The receptor, a vital inflammation switch, is an adenosine triphosphate (ATP) gated ion channel found in several cell types. Recommended Reports Reports Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2) Drugs in Development by Therapy Areas... GlobalData Reports D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Drugs in Development by Therapy Areas and Ind... GlobalData View all Companies Intelligence Breye Therapeutics ApS View all The oral P2X7 receptor antagonists offer a new treatment approach for both early-stage diabetic retinopathy (DR) and dry age-related macular degeneration (dry AMD). Golgi Neurosciences managing director Chiara Liberati said: “With leading experts on the Scientific Advisory Board, Breye is led by a strong and seasoned Management team, supported by a highly-regarded syndicate of investors, making Breye the ideal partner to facilitate the next steps in advancing our P2X7 receptor antagonist program towards developing innovative approaches for retinal disorders.” DR impacts around 30% of individuals with diabetes and is one of the main reasons for blindness among working-age adults. AMD is a significant factor contributing to the loss of vision, especially among individuals aged 60 years and older. Breye Therapeutics CEO Ulrik Mouritzen said: “The Golgi incubator has fantastic expertise in neurosciences, and we are pleased to collaborate to advance the P2X7 receptor antagonist programme for retinal disorders, where there is a large unmet medical need for more effective and less burdensome therapies.” Based in Milan, Italy, Golgi is involved in the discovery and development of small molecule-based therapies for neurodegenerative diseases. Breye is focused on the development of novel, oral ophthalmology drugs for DR and AMD.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis